Gene · 7150
Papers4,103
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
501 to 520 of 4,103
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Understanding the Human RECQ5 Helicase-Connecting the Dots from DNA to Clinics. | Cells | 2023 | 37626846 | PubTator, text mining | PubMed |
| Mesonephric-like Adenocarcinoma of the Uterine Corpus: Genomic and Immunohistochemical Profiling with Comprehensive Clinicopathological Analysis of 17 Consecutive Cases from a Single Institution. | Biomedicines | 2023 | 37626765 | PubTator, text mining | PubMed |
| BRD7 suppresses tumor chemosensitivity to CHK1 inhibitors by inhibiting USP1-mediated deubiquitination of CHK1. | Cell Death Discov | 2023 | 37626049 | PubTator, text mining | PubMed |
| Yeast transcription factor Msn2 binds to G4 DNA. | Nucleic Acids Res | 2023 | 37615577 | PubTator, text mining | PubMed |
| p53-dependent R-loop formation and HPV pathogenesis. | Proc Natl Acad Sci U S A | 2023 | 37611058 | PubTator, text mining | PubMed |
| RNF4 and USP7 cooperate in ubiquitin-regulated steps of DNA replication. | Open Biol | 2023 | 37607592 | PubTator, text mining | PubMed |
| R-loops, type I topoisomerases and cancer. | NAR Cancer | 2023 | 37600974 | PubTator, text mining | PubMed |
| XAF1 promotes anti-RNA virus immune responses by regulating chromatin accessibility. | Sci Adv | 2023 | 37595039 | PubTator, text mining | PubMed |
| Integrated multi-omics analyses reveal Jorunnamycin A as a novel suppressor for muscle-invasive bladder cancer by targeting FASN and TOP1. | J Transl Med | 2023 | 37587470 | PubTator, text mining | PubMed |
| Mechanistic study of dual-function inhibitors targeting topoisomerase II and Rad51-mediated DNA repair pathway against castration-resistant prostate cancer. | Prostate | 2023 | 37583103 | PubTator, text mining | PubMed |
| Applications of nanotechnologies for miRNA-based cancer therapeutics: current advances and future perspectives. | Front Bioeng Biotechnol | 2023 | 37576994 | PubTator, text mining | PubMed |
| Elucidation of Pharmacological Mechanism Underlying the Anti-Alzheimer's Disease Effects of Evodia rutaecarpa and Discovery of Novel Lead Molecules: An In Silico Study. | Molecules | 2023 | 37570816 | PubTator, text mining | PubMed |
| CSB Regulates Pathway Choice in Response to DNA Replication Stress Induced by Camptothecin. | Int J Mol Sci | 2023 | 37569794 | PubTator, text mining | PubMed |
| Inhibition of Topoisomerases by Metal Thiosemicarbazone Complexes. | Int J Mol Sci | 2023 | 37569386 | PubTator, text mining | PubMed |
| Epigenetically upregulating TROP2 and SLFN11 enhances therapeutic efficacy of TROP2 antibody drug conjugate sacitizumab govitecan. | NPJ Breast Cancer | 2023 | 37567892 | PubTator, text mining | PubMed |
| Alkylation of nucleobases by 2-chloro-N,N-diethylethanamine hydrochloride (CDEAH) sensitizes PARP1-deficient tumors. | NAR Cancer | 2023 | 37554969 | PubTator, text mining | PubMed |
| Proteomics-based identification of proteins in tumor-derived exosomes as candidate biomarkers for colorectal cancer. | World J Gastrointest Oncol | 2023 | 37546562 | PubTator, text mining | PubMed |
| Flipons and small RNAs accentuate the asymmetries of pervasive transcription by the reset and sequence-specific microcoding of promoter conformation. | J Biol Chem | 2023 | 37544644 | PubTator, text mining | PubMed |
| The MLL-Menin Interaction is a Therapeutic Vulnerability in NUP98-rearranged AML. | Hemasphere | 2023 | 37520776 | PubTator, text mining | PubMed |
| A Moexitecan Magnetic Liposomal Strategy for Ferroptosis-Enhanced Chemotherapy. | Pharmaceutics | 2023 | 37514198 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/7150/papers?page=26